Equillium Inc
NASDAQ:EQ
Equillium Inc
Cash Equivalents
Equillium Inc
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Cash Equivalents
$15.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash Equivalents
$5.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash Equivalents
$10B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash Equivalents
$12B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash Equivalents
$6.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash Equivalents
$17.9B
|
CAGR 3-Years
84%
|
CAGR 5-Years
62%
|
CAGR 10-Years
39%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Cash Equivalents?
Cash Equivalents
15.4m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Cash Equivalents amounts to 15.4m USD.
What is Equillium Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash Equivalents growth was -55%. The average annual Cash Equivalents growth rates for Equillium Inc have been -42% over the past three years , -11% over the past five years .
You don't have any saved screeners yet